UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Multiple sclerosis, 2008-11, Vol.14 (9), p.1157-1174

2008

Volltextzugriff (PDF)

Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial

Neurology, 2002-11, Vol.59 (10), p.1496-1506

2002

Volltextzugriff (PDF)

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Neurology, 1998-03, Vol.50 (3), p.701-708

1998

Volltextzugriff (PDF)

Influence of infection on exacerbations of multiple sclerosis

Annals of neurology, 1994, Vol.36 (S1), p.S25-S28

Panitch, Hillel S.

1994

Volltextzugriff (PDF)

Developmental changes in chest wall compliance in infancy and early childhood

Journal of applied physiology (1985), 1995-01, Vol.78 (1), p.179-184

1995

Volltextzugriff (PDF)

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

Neurology, 2008-03, Vol.70 (13 Pt 2), p.1134-1140

2008

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-08, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-04, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

The Lancet (British edition), 2005-08, Vol.366 (9485), p.579-582

2005

Volltextzugriff (PDF)

Bronchiolitis in infants

Current opinion in pediatrics, 2001-06, Vol.13 (3), p.256-260

Panitch, H B

2001

Volltextzugriff (PDF)

Interferons in multiple sclerosis : a review of the evidence

Drugs (New York, N.Y.), 1992-12, Vol.44 (6), p.946-962

PANITCH, H. S

1992

Volltextzugriff (PDF)

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis

Clinical therapeutics, 2007-09, Vol.29 (9), p.2031-2048

2007

Volltextzugriff (PDF)

Respiratory Care of the patient with duchenne muscular dystrophy: ATS Consensus statement

American journal of respiratory and critical care medicine, 2004-08, Vol.170 (4), p.456-465

2004

Volltextzugriff (PDF)

A70 PULMONARY REHABILITATION IN LUNG TRANSPLANTATION AND THE ACUTE SETTING: View Of Directors Of Home Ventilation Programs On Decisions Around Long-Term Ventilation

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Chest wall compliance in infants and children with neuromuscular disease

American journal of respiratory and critical care medicine, 1996-10, Vol.154 (4 Pt 1), p.1045-1048

1996

Volltextzugriff (PDF)

B52 NEONATAL LUNG DISEASE: FROM BENCH TO BABIES: Bethanechol Improves Respiratory Symptoms In Young Children With Tracheomalacia

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

D25 NEONATAL AND CONGENITAL LUNG DISEASES: Outcomes In Neonates With Bronchopulmonary Dysplasia And Tracheobronchomalacia

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

Neurology, 2007-10, Vol.69 (14), p.1391-1403

2007

Volltextzugriff (PDF)

D25 NEONATAL AND CONGENITAL LUNG DISEASES: Airway Reactivity In Preterm Infants Is Associated With Increased Respiratory Morbidity In The First Year Of Life

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Nature medicine, 2000-10, Vol.6 (10), p.1176-1182

2000

Volltextzugriff (PDF)

The effect of interferon-β on mouse neural progenitor cell survival and differentiation

Biochemical and biophysical research communications, 2009-10, Vol.388 (2), p.181-186

2009

Volltextzugriff (PDF)

Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response

Journal of neuroimmunology, 2007-04, Vol.185 (1), p.168-174

2007

Volltextzugriff (PDF)

Quantitative bronchoscopic assessment of airway collapsibility in newborn lamb tracheae

Pediatric research, 1998-06, Vol.43 (6), p.832-839

1998

Volltextzugriff (PDF)

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Journal of the neurological sciences, 2005-12, Vol.239 (1), p.67-74

2005

Volltextzugriff (PDF)

Clinical trials of interferons in multiple sclerosis what have we learned?

Journal of neuroimmunology, 1993-07, Vol.46 (1), p.155-164

1993

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Influence of infection on exacerbations of multiple sclerosis

Developmental changes in chest wall compliance in infancy and early childhood

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

Bronchiolitis in infants

Interferons in multiple sclerosis : a review of the evidence

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis

Respiratory Care of the patient with duchenne muscular dystrophy: ATS Consensus statement

A70 PULMONARY REHABILITATION IN LUNG TRANSPLANTATION AND THE ACUTE SETTING: View Of Directors Of Home Ventilation Programs On Decisions Around Long-Term Ventilation

Chest wall compliance in infants and children with neuromuscular disease

B52 NEONATAL LUNG DISEASE: FROM BENCH TO BABIES: Bethanechol Improves Respiratory Symptoms In Young Children With Tracheomalacia

D25 NEONATAL AND CONGENITAL LUNG DISEASES: Outcomes In Neonates With Bronchopulmonary Dysplasia And Tracheobronchomalacia

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

D25 NEONATAL AND CONGENITAL LUNG DISEASES: Airway Reactivity In Preterm Infants Is Associated With Increased Respiratory Morbidity In The First Year Of Life

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

The effect of interferon-β on mouse neural progenitor cell survival and differentiation

Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response

Quantitative bronchoscopic assessment of airway collapsibility in newborn lamb tracheae

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Clinical trials of interferons in multiple sclerosis what have we learned?

Aktive Filter

Suchergebnisse filtern